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p53 codon 72 polymorphism and hypopharyngeal cancer
Background: p53 polymorphism at codon 72 is a known risk marker for various malignancies, but it has not
been studied in hypopharyngeal cancer. This study investigated the genotype distribution of p53 codon 72
polymorphism in hypopharyngeal cancer patients and non-cancer controls matched for age, gender, alcohol
consumption and smoking habit.
Methods: Genomic DNA was extracted from peripheral blood cells of 53 patients with hypopharyngeal
cancer and 53 non-cancer controls. Codon 72 polymorphism of p53 was identified by polymerase chain
reaction–restriction fragment length polymorphism.
Results: Patients with hypopharyngeal cancer had higher frequencies of Pro/Pro (26.4% vs. 13.2%) and Pro/
Arg (51.0% vs. 45.3%) but lower frequencies of Arg/Arg (22.6% vs. 45.1%) compared to controls. Compared
to Arg/Arg genotypes, Pro/Pro genotypes had a relative risk of hypopharyngeal cancer of 3.667 (95% confidence
interval, 1.16–11.56; p = 0.03). As a group, patients with Pro/Pro or Arg/Pro who were carriers of the Pro
allele had a higher relative risk of hypopharyngeal cancer compared to Arg homozygous carriers (odds ratio,
2.415; 95% confidence interval, 1.04–5.64; p = 0.04).
Conclusion: This study demonstrated that p53 codon 72 Pro homozygosity is associated with a higher risk
of developing hypopharyngeal cancer. [J Formos Med Assoc 2006;105(2):99–104]
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Squamous cell carcinoma of the hypopharynx is
one of the most malignant of all head and neck
cancers because of its high incidence of locoregion-
al recurrence and distant metastasis. Despite re-
cent advances in surgery, radiotherapy and chemo-
therapy, the reported 5-year disease-specific sur-
vival rates from different centers worldwide ranged
from 25% to 33.4%.1 Because of difficulty in early
detection of hypopharyngeal cancer and the high
frequency of occult metastasis, most patients pre-
sent with advance-stage disease at diagnosis. Thus,
identification of new biomarkers is urgently need-
ed to determine cancer susceptibility, predict prog-
nosis and guide appropriate treatment.
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In head and neck squamous cell carcinoma
(HNSCC), the p53 gene is frequently either mutat-
ed or shows altered expression of the gene pro-
duct.2,3 Polymorphism in the wild-type p53 gene
at codon 72 of exon 4 has been described, result-
ing in either a proline (CCC) or an arginine (CGC)
residue.4 The association of polymorphism at
codon 72 in the p53 gene with susceptibility to
cancers of the cervix,5–11 lung,12–18 bladder,19–21
prostate,22 skin,23,24 esophagus,25,26 stomach,27 and
breast28–30 has been studied. However, studies
of the role of p53 codon 72 polymorphism in
HNSCC have been limited,31–33 and specific stud-
ies on hypopharyngeal cancer are lacking. This
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let was treated by adding 2–4 mL TRIzole (GIBCO/
BRL, Bethesda, MD, USA) at room temperature
for 5 minutes. The organic phase was collected
and mixed with 0.3 mL 100% ethanol/1 mL TRI-
zole at room temperature for 3 minutes. The re-
sulting DNA pellet was transferred to a new 1.5
mL Eppendorf tube. The DNA pellet was washed
twice in 1 mL 10% ethanol/0.1 M sodium citrate,
and then subjected to 1 mL 75% ethanol at room
temperature for 15 minutes. Pelleted DNA was
vacuum-dried and resuspended in 8 mM NaOH.
After quantification by spectrophotometry, the
DNA was divided into different vials and stored at
–30$C until use.
Genotyping
Purified genomic DNA was amplified by polymer-
ase chain reaction (PCR) using standard buffer,
nucleotides, Taq DNA polymerase and the primer
pairs (forward, 5’-TGAGGACCTGGTCCTCTGACT-
3’; reverse, 5’-AAGAGGAATCCCAAAGTTCCA-3’).
The PCR protocol consisted of an initial melting
step of 94$C for 5 minutes, 40 cycles of 94$C for
30 seconds, 60$C for 30 seconds, and 72$C for 30
seconds, and a final extension step of 72$C for 10
minutes. The PCR products were purified and di-
gested with 5 U of BstU I (New England Biolabs,
Beverly, MA, USA) in a buffer containing 25 mM
Tris/acetate (pH 7.8), 100 mM potassium acetate,
10 mM magnesium acetate, and 1 mM dithio-
threitol, and incubated at 37$C for 15 hours. An
aliquot was subjected to electrophoresis on 2%
agarose gel and bands were visualized with ethi-
dium bromide. The arginine form of codon 72 con-
tains a BstU I site that is not present in the proline
allele. The Arg allele, when cleaved by the BstU I
enzyme, yields two fragments of 253 bp and 161
bp, while the Pro allele remained as a 414-bp sin-
gle band on the gel. Patients with the heterozygous
Arg/Pro will produce three bands (Figure 1). To
verify the accuracy of the genotyping obtained by
this PCR and restriction fragment length polymor-
phism (RFLP) technique, we performed direct se-
quencing of PCR products from 30 randomly
selected patients. All tested samples were confirmed
by accurate sequencing data (Figure 2).
study investigated the genotype distribution of
p53 codon 72 polymorphism and its association
with risk of hypopharyngeal cancer.
Methods
Study population
Between July 2000 and February 2003, 53 patients
with pathologically-confirmed squamous cell car-
cinoma of the hypopharynx were enrolled in this
study after informed consent was obtained. A con-
trol group was selected by screening 53 subjects
from health examination clinics, matched for age,
gender, alcohol consumption, smoking habit,
and no past history of malignancy. A 10 mL pe-
ripheral blood sample was collected from all pa-
tients and controls.
Blood processing and DNA extraction
Whole blood samples were centrifuged at 1000g
for 15 minutes. The supernatant was discarded.
The erythrocytes were lysed by incubating with
40–45 mL lysis buffer (155 mmol/L NH4Cl, 7.5
mmol/L KHCO3, 2.5 mmol/L K2CO3, 0.1 mmol/L
EDTA; pH 7.8) on ice for 15 minutes, and vortexed
briefly twice during incubation. Immediately after
centrifugation, the cell pellet was washed twice in
phosphate-buffered saline (pH 7.3). The cell pel-
414 bp
253 bp
161 bp
M 1 2 3 4 5 6 7 8
Figure 1. Polymerase chain reaction–restriction fragment length polymorphism
analysis of the p53 gene. The Pro allele is not cleaved by BstU I at codon 72 and
has a single band with a fragment length of 414 bp. The Arg allele is cleaved by
BstU I and yields two small fragments (253 bp and 161 bp). The heterozygote has
three bands (414 bp, 253 bp, 161 bp). Lane M = 100 bp ladder DNA marker; Lanes
1 and 7 = Arg/Arg; Lanes 2 and 6 = Pro/Pro; Lanes 3, 4, 5 and 8 = Arg/Pro.
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Statistical analysis
The chi-square test was used to compare the geno-
type frequencies of the p53 gene polymorphism
between hypopharyngeal cancer patients and
controls. A p value of less than 0.05 was consid-
ered to be statistically significant. The association
between p53 codon 72 polymorphism and hy-
popharyngeal cancer was estimated by computing
the odds ratio (OR) and 95% confidence interval
(CI) by logistic regression analysis. All statistical
analyses were performed using SPSS version 10.0
software (SPSS Inc, Chicago, IL, USA).
Results
All patients and controls were male and had simi-
lar smoking and alcohol consumption habits. The
mean age of patients was 60.5 years (range, 33–86
years) and of controls was 58.1 years (range, 33–
81 years).
The distribution of p53 genotypes among con-
trols and patients is shown in the Table. For pa-
tients with hypopharyngeal cancer, frequencies for
the Arg/Arg, Arg/Pro and Pro/Pro genotypes were
22.6%, 51.0% and 26.4%, respectively. In controls,
these frequencies were 41.5%, 45.3% and 13.2%,
respectively (p = 0.07). Compared to Arg/Arg
genotypes, Pro/Pro genotypes had a relative risk
of hypopharyngeal cancer of 3.667 (95% CI, 1.16–
11.56; p = 0.03). The relative risk of hypopharyn-
geal cancer among Arg/Pro genotypes was 1.778
(95% CI, 0.62–5.14; p = 0.29). Patients with Arg/
Pro or Pro/Pro genotype who were carriers of the
Pro allele had a higher relative risk of hypopha-
ryngeal cancer compared to Arg homozygotes (OR,
2.415; 95% CI, 1.04–5.64; p = 0.04).
According to the 1997 TNM staging system of
the American Joint Committee on Cancer, 47 pa-
tients presented with stage IV, two with stage II
and four with stage III disease. For patients with
stage IV disease, frequencies of the Arg/Arg, Arg/
Pro and Pro/Pro genotypes were 21.3%, 48.9% and
29.8%, respectively. For patients with stage II/III
disease, the frequencies of the Arg/Arg, Arg/Pro and
Pro/Pro genotypes were 33.3%, 66.7% and 0%,
respectively. Analysis of whether or not there was
an association between p53 codon 72 polymor-
phism and stage was not meaningful in this study
because of the small sample size of patients with
stage II/III disease.
Discussion
There is increasing evidence suggesting that host
factors, including genetic polymorphisms, may
explain some of the individual differences in can-
Table.  Distributions of codon 72 polymorphism in patients and controls
Patients (n = 53) Controls (n = 53) OR (95% CI) p
Arg/Arg 12 (22.6%) 22 (41.5%) 1
Arg/Pro or Pro/Pro 41 (77.4%) 31 (58.5%) 2.415 (1.043–5.639) 0.040
Arg/Pro 27 (51.0%) 24 (45.3%) 1.778 (0.615–5.136) 0.288
Pro/Pro 14 (26.4%) 07 (13.2%) 03.667 (1.163–11.557) 0.027
OR = odds ratio; CI = confidence interval.
Figure 2. Direct sequencing data confirm results of the polymerase chain reaction–
restriction fragment length polymorphism analysis.
Pro
Pro/Arg
Arg
Codon 72
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cer occurrence. The p53 tumor suppressor gene,
located on chromosome 17p13, is one of the most
commonly mutated genes in all types of human
cancer.34 After DNA-damaging insult, wild-type
p53 induces either growth arrest or apoptosis.35 Mu-
tations within p53 abolish these activities and al-
low uncontrolled proliferation of cells harboring
mutations, ultimately resulting in the progression
to cancer.36
The proline-rich domain of p53 has been shown
to be necessary for its ability to induce apoptosis
and growth suppression.37,38 Interestingly, within
this domain, there is a common polymorphism at
position 72 encoding either an arginine or a pro-
line residue.4 Both variant alleles differ in biochem-
ical and biologic activity.39 Several mechanisms
have been proposed to explain the role of the Arg
allele in cancer development. The Arg allele has
weaker affinity for several transcription-activating
factors in vitro.39 In addition, the Arg allele has been
shown to be more susceptible to degradation by
the human papillomavirus (HPV) E6 protein than
the Pro allele in vivo.5 The Arg allele may enhance
mutant p53 binding to p73, thus neutralizing p73-
induced apoptosis independently of HPV-related
mechanisms in squamous cell cancers.40,41
Many previous studies have investigated the
association between p53 codon 72 polymorphism
and the risk of various cancers. Carcinomas of
the cervix and lung were the most frequently in-
vestigated. Storey et al first suggested that p53
codon 72 polymorphism played a role in the de-
velopment of HPV-related cancers.5 They showed
that women with the Arg/Arg genotype variant were
seven times more susceptible to HPV-associated
cervical cancer than heterozygotes. However,
subsequent studies did not consistently confirm
this association.6–11 A meta-analysis of 50 articles
of cervical neoplasia showed that there was no
evidence of association or heterogeneity for pre-
invasive lesions.42 For invasive cervical cancer with
undefined histology, the Arg/Arg genotype was not
found to affect risk (OR, 1.1; 95% CI, 0.9–1.3).
Only a slightly increased risk was observed for
squamous cell carcinoma (OR, 1.5; 95% CI, 1.2–
1.9) and adenocarcinoma (OR, 1.7; 95% CI, 1.0–
2.7). Three large case-control studies found that
the p53 Pro allele was associated with an increased
risk of lung cancer, especially in adenocarcinoma
rather than squamous cell carcinoma.14–16 However,
a recent systematic review and meta-analysis
showed little support for this hypothesis.43 These
conflicting results from epidemiologic and func-
tional studies of p53 codon 72 polymorphism sug-
gest that the Arg and Pro alleles may play different
roles in different types of cancers, depending on
the interplay of each allele with different patho-
gens.
Compared with other types of cancer, there has
been little study of the association of p53 codon
72 polymorphism with HNSCC.31–33 Indeed, tu-
mors arising from the head and neck region con-
tain many different anatomic sites with different
behaviors. Recently, three large case-control stud-
ies of HNSCC failed to demonstrate a positive as-
sociation with p53 codon 72 polymorphism.31–33
Another two studies also failed to identify any evi-
dence for association between p53 codon 72 poly-
morphism and risk of oral cancer in subjects with
or without HPV infection.44,45 Oral cancers occur
in a heterogeneous group of patients with tumors
arising from the buccal mucosa, gingiva, tongue,
hard palate, and lip. However, previous studies
of specific types of head and neck cancers usually
found positive association with p53 codon 72
polymorphism, such as nasopharyngeal carcino-
ma46 and laryngeal tumors.47 In the present study,
we demonstrated a positive association of hy-
popharyngeal cancer with p53 codon 72 poly-
morphism.
The genotype distribution of p53 codon 72
polymorphism shows significant variation among
ethnic groups. Beckman et al reported a significant
decrease in the frequency of the Pro allele with in-
creasing latitude, ranging from 0.63 in African
Blacks to 0.17 in Swedish Saamis.48 Weston et al
also reported that the frequency of the Pro allele
varied by ethnicity.49 The p53 Pro allele was found
to be more common in African-Americans (0.50)
than in Caucasians (0.29). Two Japanese studies
showed genotype frequencies of the Pro allele rang-
ing from 0.35 to 0.40.13,17
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In order to clarify the extent of possible bias in
the selection of the control group for this study,
we compared the characteristics of our control
group with control groups in various previous stud-
ies of p53 codon 72 polymorphism in patients with
cancer in Taiwan.18,23,26,46,50 No significant difference
in p53 codon 72 polymorphism distribution in
non-cancer controls was found between our study
and those previous studies. The Pro/Pro genotype
frequency in our controls was 13.2%, which was
in the range of other Taiwanese series (12.0–
19.7%).18,23,26,46,50 Another interesting finding from
our literature review is that Taiwanese patients with
the Pro/Pro genotype have a significantly higher
risk of upper aerodigestive cancers, including car-
cinomas of the nasopharynx (OR, 3.0; p < 0.05),46
hypopharynx (the current study: OR, 2.42; p =
0.04), esophagus (OR, 2.2; p < 0.05),26 and lung
(OR, 3.14; p = 0.003).18
In conclusion, our data show that the Pro/Pro
genotype may be a useful marker for identifying
individuals susceptible to the development of hy-
popharyngeal cancer and possibly other upper
aerodigestive cancers.
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